[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"healthy-participants-study\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:healthy-participants-study":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,49,75,99,128,150,171,202,224,250],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100648450","early-phase-1-a-single-and-multiple-ascending-dose-trial-assessing-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-zp6590-in-participants-with-normal-weight-overweight-and-obesity-100648450",false,"NCT07721597","A Single and Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP6590 in Participants With Normal Weight, Overweight and Obesity","A First-in-human, Randomized, Single and Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP6590 in Participants With Normal Weight, Overweight and Obesity","Inclusion Criteria:\n\nSAD-Part:\n\n* Male participant\n* Age between 18 and 55 years, both inclusive\n* Body Mass Index (BMI) between 20.0 and 29.9 kg\u002Fm\\^2, both inclusive\n\nMAD-Part:\n\n* Male participant\n* Age between 18 and 60 years, both inclusive\n* Body Mass Index (BMI) between 27.0 and 39.9 kg\u002Fm\\^2, both inclusive\n\nExclusion Criteria:\n\nSAD-Part and MAD-Part:\n\n* Any clinically significant abnormal haematology, biochemistry, or urinalysis screening tests, as judged by the investigator\n* Treatment for weight management within 3 months before randomization in this trial",true,"MALE","18 Years","60 Years",{"count":21,"type":22},88,"ESTIMATED","INTERVENTIONAL",[25],"EARLY_PHASE1","The goal of this clinical trial is to learn about the safety and tolerability of drug ZP6590 and to learn how the body processes the drug ZP6590 in adults. The main questions it aims to answer are:\n\n* Is the drug ZP6590 safe and well tolerated when administered as escalating single and multiple doses of the ZP6590?\n* How quickly and to what extent the administered investigational drug is absorbed and distributed, and how long it takes to be eliminated from the body?\n\nIn the first Part of the study:\n\nParticipants will:\n\n• Get a single ascending dose of the drug ZP6590 or placebo and will have an observation period of 4 weeks.\n\nIn the second Part of the study:\n\nParticipants will:\n\n• Get multiple dosages of the drug ZP6590 or placebo for 6 or 12 weeks followed by an observation period of 6 weeks after last dosing.",[28,29,30],"Healthy Participants Study","Overweight and Obese Adults","First in Man Study to Evaluate Initial Safety",[32,33,34,35],"ZP6590","Safety and Tolerability","GIP-R agonist","obesity","RECRUITING","2026-08-12",{"date":39,"type":40},"2026-08-13","ACTUAL",{"date":42,"type":40},"2026-07-09",{"date":44,"type":22},"2027-09-06",{"name":46,"class":47},"Zealand Pharma","INDUSTRY",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":16,"sex":56,"minAge":18,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":62,"conditions":63,"keywords":64,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":48},"100651129","phase-1-phase-i-clinical-study-of-zl-65-tablet-in-healthy-adult-participants-in-china-100651129","NCT07757152","Phase I Clinical Study of ZL-65 Tablet in Healthy Adult Participants in China","Phase I Clinical Study of ZL-65 Tablet in Healthy Adult Participants in China: Randomized, Double-blind, Placebo-controlled, Single\u002FMultiple Oral Dose Escalation for Safety Tolerability, Pharmacokinetics, Preliminary Pharmacodynamics, and Food Effect","Inclusion Criteria:\n\n1. Healthy adult participants for the Chinese trial, gender-neutral, aged 18 to 45;\n2. Male trial participants weighing \\>= 50.0 kg, female trial participants weighing \\>=45.0 kg, with a body mass index (BMI) between 19.0 and 28.0 kg\u002Fm\\^2;\n3. Those who can understand the informed consent form, voluntarily participate in the experiment, and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Individuals with allergies or a history of clinically significant food, drug allergies, or other allergic diseases as determined by researchers; Or those who are known to be allergic to NLRP3 inhibitors or to the excipients contained in the test drug;\n2. .Individuals with any serious illness or medical history of cardiovascular system, digestive system, urinary system, respiratory system, nervous system, immune system, endocrine system, malignant tumors, mental illness, etc;\n3. Pregnant or lactating women or women of childbearing age who have had unprotected sexual intercourse with their partners within 14 days prior to screening; Or those with positive results in blood pregnancy test;\n4. Within 48 hours prior to administration, consuming any food or beverage containing caffeine, or fruits or vegetables containing grapefruit juice, soybeans, flavonoids that may affect metabolic enzymes, or consuming foods or beverages containing alcohol。","ALL","45 Years",{"count":59,"type":22},108,[61],"PHASE1","To evaluate the tolerability and safety of a single oral dose of ZL-65 tablets in healthy adult trial participants through dose escalation; and to preliminarily assess the pharmacokinetic and pharmacodynamic characteristics of a single oral dose of ZL-65 tablets.Exploring the impact of food intake on the PK of orally administered ZL-65 tablets in healthy adult trial participants.",[28],[65],"ZL65","2026-08-05",{"date":68,"type":40},"2026-08-11",{"date":70,"type":40},"2026-07-23",{"date":72,"type":22},"2027-12-30",{"name":74,"class":47},"Chengdu Zenitar Biomedical Technology Co., Ltd",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":16,"sex":56,"minAge":18,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":85,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":48},"100647808","phase-1-a-phase-1-first-in-human-study-of-cnd319-in-healthy-participants-and-patients-with-rheumatic-diseases-100647808","NCT07712939","A Phase 1, First-in-Human Study of CND319 in Healthy Participants and Patients With Rheumatic Diseases","A Phase 1, First-In-Human, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CND319 in Healthy Participants and Patients With Rheumatic Diseases","Inclusion Criteria (SAD):\n\n1. 18 to 65 years old\n2. Body mass index 18-30 kg\u002Fm2 and weight 55-100 kg\n3. Individuals in good health\n4. Agree to abstain from consumption of alcohol 48 hours prior to study visits\n5. Agree to the use of highly effective contraception as defined in the protocol\n\nInclusion Criteria (MAD and Part 2 Expansion):\n\nPatients with RA:\n\n1. 18 to 75 years old\n2. Diagnosis of adult-onset RA\n3. Class I-III RA\n4. Moderately to severely active RA\n\nPatients with SjD:\n\n1. 18 to 75 years old\n2. Diagnosis of primary SjD\n\nExclusion Criteria (SAD):\n\n1. Inadequate clinical laboratory parameters at Screening\n2. Active infection\n3. Receipt of or inability to discontinue any excluded therapies\n4. Individuals with immediate household contact with your children (eg, ≤ 6 years old) or immunocompromised persons\n5. History of alcohol or drug abuse within last 12 months\n6. Positive alcohol breathalyzer or drug screen prior to dosing\n7. Inability to comply with protocol-mandated requirements\n8. History of severe allergic or anaphylactic reactions to mAb therapy (or recombinant anti-body-related fusion proteins) or any constituents of study drug\n9. Major surgery requiring use of general anesthesia within 12 weeks or planned or expected major surgery during the study\n10. Blood donation or significant blood loss within 30 days\n11. Individuals considered to be part of a vulnerable population (eg, incarceration)\n12. Individuals that in the opinion of the Investigator, are not suitable for participation in the trial\n\nExclusion Criteria for patients with RA or SjD:\n\n1. Inadequate clinical laboratory parameters at Screening\n2. Active infection\n3. Receipt of or inability to discontinue any excluded therapies\n4. History of progressive multifocal leukoencephalopathy\n5. Central nervous system disease\n6. Presence of 1 or more significant concurrent medical conditions\n7. Have a diagnosis or history of malignant disease within 5 years\n8. History of severe allergic or anaphylactic reactions to mAb therapy (or recombinant antibody-related fusion proteins) or any constituents of study drug\n9. Women who are pregnant or breastfeeding\n10. Patients who do not agree to the use of highly effective contraception as defined by the protocol","65 Years",{"count":84,"type":22},105,[61],"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary clinical activity of CND319 in healthy adult participants and patients with rheumatic diseases.",[28,88,89],"Rheumatoid Arthritis","Sjogren's Syndrome","2026-07-21",{"date":92,"type":40},"2026-07-22",{"date":94,"type":22},"2026-07-20",{"date":96,"type":22},"2028-03-31",{"name":98,"class":47},"Candid Therapeutics",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":16,"sex":56,"minAge":18,"maxAge":82,"enrollmentInfo":106,"targetDuration":4,"studyType":23,"phases":108,"briefSummary":109,"conditions":110,"keywords":111,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":48},"100646277","phase-1-neural-effects-of-intravenous-nn-dimethyltryptamine-dmt-100646277","NCT07693257","Neural Effects of Intravenous N,N-dimethyltryptamine (DMT)","Neural Effects of Continuous Intravenous Infusion of N,N-dimethyltryptamine (DMT)","Inclusion Criteria:\n\n* 18 to 65 years of age\n* Able to fluently communicate in English\n* Agree to sign the consent and HIPAA authorization\n* Not taking serotonergic antidepressant medication\n* Willing to refrain from using any non-prescribed psychoactive drugs, including alcohol, within 24 hours before and after study drug administration\n* Willing to refrain from consumption of illicit psychoactive substances during the study\n* Agree not to use any nonprescription medications, herbal medications, or supplements during the week prior to each drug session unless an exception is approved by the study investigators\n* Willing to refrain from smoking or use of nicotine from 8:00 AM on the morning of drug sessions until discharge at the end of the session\n* Have used classic serotonergic hallucinogens (e.g., LSD, psilocybin mushrooms, ayahuasca) without untoward\u002Fadverse effects and report \"liking\" psychedelic drugs with no previous adverse reactions to DMT or other psychedelics\n* Report at least 20 lifetime uses of psychedelics, including at least 5 uses of DMT (any form), at least one via inhalation, at least once within the past 2 years, and not within the past 3 months\n* Able to remain in an fMRI scanner without sedation and pass fMRI safety screening\n* Refrain from caffeine use prior to fMRI scanning\n* Women of childbearing potential must agree to use effective birth control from screening through the final visit\n* Have a relative or friend available to provide transportation after the drug session\n* Not taking medications acting as serotonin antagonists (e.g., cyclobenzaprine, ondansetron), dopamine antagonists (e.g., metoclopramide, promethazine, prochlorperazine), dopamine agonists (e.g., levodopa, pramipexole, apomorphine), psychostimulants (e.g., modafinil, armodafinil, solriamfetol, methylphenidate, dexmethylphenidate, atomoxetine, dextroamphetamine, mixed amphetamine salts, lisdexamfetamine), anticholinergics (e.g., benztropine, trihexyphenidyl, scopolamine, hyoscyamine), or NMDA receptor antagonists (e.g., amantadine, memantine, ketamine)\n\nExclusion Criteria:\n\n* Pregnant or nursing females\n* Females of childbearing potential who are sexually active but not using birth control\n* MRI contraindications (e.g., pacemakers, metal implants, spinal cord stimulators)\n* Current DSM-5 diagnosis of depression or anxiety (or within past 6 months), bipolar disorder, schizophrenia, or other psychotic disorder\n* First-degree relative with bipolar disorder, schizophrenia, or other psychotic disorder\n* Suicide risk as determined by clinician assessment and\u002For C-SSRS\n* Active substance use disorder (excluding tobacco and caffeine)\n* Use of serotonergic dietary supplements (e.g., 5-hydroxytryptophan, St. John's wort, SAM-e) if unwilling to discontinue for study duration\n* Neurological conditions affecting cognition or perception (e.g., dementia, traumatic brain injury, mild cognitive impairment)\n* Positive urine drug screen for amphetamines, barbiturates, buprenorphine, cocaine, methamphetamine, MDMA, methadone, opiates, or phencyclidine\n* Use of DMT or another serotonergic hallucinogen within the past 3 months\n* Concomitant treatment with antipsychotic medications\n* Concomitant treatment with antidepressants, MAO inhibitors, or serotonin reuptake inhibitors (trazodone ≤50 mg\u002Fday for insomnia allowed but not within 48 hours of DMT session)\n* Severe hearing or visual impairment\n* History of seizure disorder or epilepsy\n* History of adverse reactions to rescue medications used in the study (benzodiazepines, antipsychotics, labetalol, nitroglycerin, ondansetron)\n* Cardiovascular disease or hypertension (SBP \\>140 mmHg or DBP \\>90 mmHg)\n* Resting heart rate \\>90 bpm\n* Hypotension (SBP \\\u003C90 mmHg or DBP \\\u003C60 mmHg)\n* QTc prolongation (\\>0.045 sec for men, \\>0.047 sec for women)\n* History of stroke, angina, clinically significant ECG abnormality, or artificial heart valve\n* Severe renal impairment (GFR \\\u003C30 mL\u002Fmin\u002F1.73 m²)\n* Clinically significant laboratory abnormalities\n* History of syncope\n* History of vertigo\n* Myocardial infarction within 12 months\n* Child-Pugh class B or higher, or with alanine aminotransferase or aspartate aminotransferase \\>2x upper limit of normal\n* Concomitant medications associated with serotonin syndrome (e.g., carbamazepine, dextromethorphan, lithium, linezolid, buspirone)\n* Severely compromised hepatic function\n* Trypanophobia (fear of needles\u002Fblood)\n* Treatment with another investigational drug within 30 days of screening",{"count":107,"type":22},20,[61],"This study examines how the psychedelic substance DMT affects the human brain when administered by the intravenous (IV) route. DMT is a naturally occurring chemical in the body that is thought to help improve mood when ingested in a continuously monitored medical setting. Previous research has shown that a single IV injection of DMT can be given safely, but its effects, which include changes in perception, emotions, and thinking, usually wear off within 15-20 minutes.\n\nTo better understand what happens when DMT's effects last longer, researchers have developed a method to give DMT slowly and continuously through an IV, which safely extends its effects for up to an hour or more. In this study, healthy volunteers who have prior experience using DMT will receive low and medium doses of DMT in this extended manner through an IV for 1 hour while undergoing a brain scanning technique known as functional magnetic resonance imaging (fMRI). These scans allow researchers to see changes in brain activity and blood flow in real time.\n\nParticipants will complete psychological assessments before and after receiving DMT, and additional brain scans without DMT will be used for comparison. The researchers will also use advanced computer techniques to help identify brain patterns linked to the visual experiences people report during DMT.\n\nOverall, the goal of the study is to better understand how DMT affects the brain during an extended experience and to learn more about the biological processes behind its psychological effects.",[28],[112,113,114,115,116,117],"Intravenous DMT","DMT","Healthy","fMRI","Psychedelics","N,N-dimethyltryptamine","NOT_YET_RECRUITING","2026-07-08",{"date":42,"type":40},{"date":122,"type":22},"2026-09-01",{"date":124,"type":22},"2029-09-01",{"name":126,"class":127},"Jon Dean","OTHER",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":16,"sex":56,"minAge":18,"maxAge":82,"enrollmentInfo":135,"targetDuration":4,"studyType":23,"phases":137,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":149},"100623810","phase-1-study-of-bw-50218-in-healthy-participants-100623810","NCT07401472","Study of BW-50218 in Healthy Participants","A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered BW-50218 in Healthy Participants","Inclusion Criteria:\n\n* Capable of providing written informed consent and complying with all study procedures for the duration of the study.\n* Body weight and body mass index (BMI) within a range considered appropriate for study participation by the investigator.\n* Female participants must be non-pregnant, non-lactating, and either of non-childbearing potential or using highly effective contraception.\n* Male participants with partners of childbearing potential must agree to use effective contraception.\n\nExclusion Criteria:\n\n* Any medical condition, recent illness, or laboratory result that, in the investigator's opinion, may increase risk or interfere with participation in the study.\n* Recent hospitalization or a significant acute medical event.\n* History of cancer or any long-term medical condition that the study doctor considers clinically relevant.\n* Clinical laboratory findings outside of range which are deemed clinically significant by the investigator at screening or Day -1.\n* Positive test for hepatitis B, hepatitis C, or HIV.",{"count":136,"type":22},60,[61],"Phase 1, Single Ascending Dose Study of Subcutaneous BW-50218 in Healthy Participants",[28],"2026-06-23",{"date":142,"type":40},"2026-06-24",{"date":144,"type":40},"2026-03-12",{"date":146,"type":22},"2027-06-30",{"name":148,"class":47},"Shanghai Argo Biopharmaceutical Co., Ltd.",2,{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":16,"sex":56,"minAge":18,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":23,"phases":159,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":48},"100643355","phase-1-healthy-participants-randomized-double-blind-placebo-controlled-phase--100643355","NCT07640438","Healthy Participants Randomized, Double-blind, Placebo-controlled, Phase Ⅰ","A Phase Ⅰ Randomized, Double-blind, Placebo-controlled, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of BY002 in Healthy Participants","Inclusion Criteria:\n\n* 1\\. Male or female aged ≥18 years at the time of signing the Informed Consent Form (ICF).\n\n  2\\. At screening, body mass index (BMI) between 18 and 30 kg\u002Fm² (inclusive), with weight ≥50.0 kg for males and ≥45.0 kg for females.\n\n  3\\. Good health status determined by screening examinations. Good health status is defined as: absence of clinically relevant abnormalities or psychiatric diseases that, in the investigator's judgment, could compromise participant safety, affect the scientific validity of the study, expose the participant to unacceptable risk, or interfere with their compliance with study procedures and restrictions.\n\n  4\\. Male participants and their partners of childbearing potential must agree to use highly effective contraception during the study and for at least 12 weeks after the last dose. Male participants must refrain from donating sperm during this period. Female participants must not be pregnant or lactating. Women of childbearing potential (WOCBP) must have a negative pregnancy test at screening and be willing to use highly effective contraception throughout the study and for at least 12 weeks after the last dose. Female participants must avoid donating eggs during this period.\n\n  5\\. Participants who, after capsaicin challenge during screening, meet the criteria specified in the Capsaicin Challenge Test Operating Manual (applicable only to participants undergoing the capsaicin challenge test).\n\n  6\\. Provide written informed consent before any study-related procedures are performed.\n\nExclusion Criteria:\n\n* 1\\. Individuals with a history or current presence of clinically significant cardiovascular (e.g., hypertension), pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, musculoskeletal, rheumatologic, psychiatric, systemic, ocular, reproductive, otorhinolaryngological, dermatological, or infectious diseases, or acute disease signs, unless deemed not clinically significant by the investigator and sponsor.\n\n  2\\. Individuals who have donated blood (≥400 mL) or experienced significant blood loss (≥400 mL), donated ≥2 units of blood components, or received a blood transfusion within 2 months prior to the first dose of investigational drug; or who plan to donate blood during the study.\n\n  3\\. Individuals with allergic constitution (defined as a clear history of allergy to two or more drugs, or to two or more common foods, or to common inhaled\u002Fcontact irritants such as pollen, dust mites, pet dander, mold, etc.), or a known history of allergic reactions to any therapeutic protein drugs (including monoclonal antibodies, fusion proteins, recombinant enzymes, cytokines, peptide hormones, blood products, vaccines, etc.).\n\n  4\\. Participants who are known to be allergic to any component of the investigational drug product or to capsaicin (applicable only to participants undergoing the capsaicin challenge test), or who have other contraindications.\n\n  5\\. Alcohol abuse or frequent alcohol consumption within 6 months prior to screening, defined as weekly alcohol intake exceeding 14 units (1 unit = 360 mL of beer, 45 mL of 40% spirits, or 150 mL of wine), or unwillingness to abstain from alcohol and any alcohol-containing products during the study; or a positive alcohol breath test.\n\n  6\\. History of drug abuse within 12 months prior to screening, or positive urine drug screen result.\n\n  7\\. Smokers (defined as consuming more than 5 cigarettes or equivalent products per week), or those who cannot discontinue the use of any tobacco products during the study period.\n\n  8\\. The investigator determines that the participant's skin characteristics are unsuitable for capsaicin skin challenge (applicable only to participants undergoing the capsaicin challenge test).\n\n  9\\. Participants for whom venous blood collection is difficult.\n\n  10\\. Individuals who, as judged by the investigator, have clinically significant abnormalities in physical examination, vital signs, ECG, clinical laboratory tests (hematology, blood biochemistry, urinalysis, coagulation function), or chest X-ray at screening.\n\n  11\\. Individuals with a QT interval corrected using Fridericia's formula (QTcF) \\>450 ms for male participants or \\>470 ms for female participants on the screening electrocardiogram (ECG).\n\n  12\\. Positive result in any of the following tests: Hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (anti-HCV) antibody, anti-human immunodeficiency virus antibody (anti-HIV Ab), and specific antibody to Treponema pallidum (TP-Ab).\n\n  13\\. Individuals who have used any prescription medication, over-the-counter (OTC) drugs, traditional Chinese patent medicines, Chinese herbal medicines, vitamins, or dietary supplements within 14 days prior to the first dose or within 5 elimination half-lives or pharmacodynamic half-lives (whichever is longer) that may interfere with the study assessments.\n\n  14\\. Receipt of any vaccine within 2 weeks prior to the first dose of the investigational drug.\n\n  15\\. Individuals who have enrolled in or participated in any clinical trial containing investigational drugs or other medical research within 1 month prior to the first dose, or within 5 elimination half-lives (whichever is longer).\n\n  16\\. Individuals deemed by the investigator to be likely noncompliant during the study period, or unable to cooperate due to language barriers or intellectual disability, or otherwise unsuitable for participation in the trial.",{"count":158,"type":22},104,[61],"The objective of this clinical trial is to evaluate the safety and tolerability of BY002 in healthy subjects.\n\nInvestigators will compare BY002 to a placebo (a pharmacologically inactive substance) to assess the safety and tolerability of BY002 in healthy subjects.\n\nParticipants will undergo:\n\n1. Single\u002Fmultiple subcutaneous (SC) administrations of BY002\u002Fplacebo\n2. A 7-day safety follow-up period following the last dose",[28],"2026-06-05",{"date":164,"type":40},"2026-06-10",{"date":166,"type":40},"2026-06-01",{"date":168,"type":22},"2027-04-30",{"name":170,"class":127},"First Affiliated Hospital of Zhejiang University",{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":16,"sex":56,"minAge":178,"maxAge":179,"enrollmentInfo":180,"targetDuration":4,"studyType":23,"phases":182,"briefSummary":183,"conditions":184,"keywords":186,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":4},"100632715","phase-1-study-to-determine-the-comparative-pharmacodynamics-of-enoxaparin-sodium-biosimilar-with-that-from-clexane-100632715","NCT07517289","Study to Determine the Comparative Pharmacodynamics of Enoxaparin Sodium Biosimilar With That From Clexane","Study Name: (SPRING) Study of Pharmacodynamics and Relative Bioavailability of an Invented National Generic Enoxaparin","Inclusion Criteria:\n\n* Healthy male and female participants aged 21 to 55 years at the time of the first dose administration.\n* Body Mass Index (BMI) between 18.5 and 30 kg\u002Fm², and body weight of at least 45 kg.\n* Participants must have vital signs within the normal range, as defined below, measured at pre-dose:\n* Blood Pressure: Systolic 100-130 mmHg, Diastolic 70-90 mmHg.\n* Pulse Rate: 60-100 beats per minute (bpm).\n* Body Temperature: 36.1-37.2\n\nExclusion Criteria:\n\n* Hypersensitivity to Enoxaparin or any of the formulation excipients\n* Contraindication to enoxaparin or related group of drugs, which includes but not limited to significant bleeding disorders, thrombocytopenia, blood-clothing disorders, and increased risk of bleeding.\n* History or presence of any medical condition or disease according to the opinion of the principal Investigator\n* History or presence of significant alcoholism or drug abuse in the past one year.\n* History or presence of heavy smoking (≥10 cigarettes or consumption of tobacco products and refusal to restrain from smoking or consumption of tobacco products for 48.00 hours before dosing until checkout of the study).\n* History or presence of significant renal, hepatobiliary, or liver impairment; a medical or familial history of seizures; significant asthma, urticaria, or other allergic reactions; or any other significant medical condition as determined by the Principal Investigator or their delegate.\n* History of difficulty with donating blood or difficulty in accessibility of veins\n* Use of any prescribed medication, OTC medicines or herbal medicines during the last two weeks preceding the first dosing\n* Participants who have any food allergy, intolerance, restriction, or special diet during the four weeks before screening\n* Participation in a drug research study within the past 2 months planned day of first dose administration\n* Donation of blood in the past 2 months before screening\n* Refusal to abstain from food (fasting) for at least ten hours before dosing\n* Refusal to abstain from alcohol or methylxanthine-containing beverages\n* Participants with a positive test for HBs-Ag, HIV-Ab, or HCV-Ab\n* Participant with a positive drug abuse test in urine at screening or at the time of check-in\n* Participant with abnormal baseline coagulation parameters, such as prolonged PT (if greater than 1.2 to 1.5 times the ULN of approximately 11 to 15 seconds), aPTT (if greater than 1.5 to 2.5 times the ULN of 25 to 40 seconds), or INR values (is above 1.4) outside the normal reference range.\n\nThis is to minimize bleeding risk and confounding effects on study outcomes.","21 Years","55 Years",{"count":181,"type":22},26,[61],"An Open-Label, Single-center, Randomized, Single-Dose, Two-Way Crossover Biosimilarity Study to Determine the Comparative Pharmacodynamics of Enoxaparin Sodium Biosimilar 40mg\u002F0.4ml with that from the Reference IMP, Clexane® (40 mg\u002F0.4ml), Following Single-Dose Administration in Healthy Participants. Test: Enoxaparin Sodium (Enoxaparin Sodium 40mg\u002F0.4ml) manufactured by EIPICO, Egypt. Reference: Clexane (Enoxaparin Sodium 40mg\u002F0.4ml) manufactured by Sanofi Aventis, Egypt. Primary objective:\n\nTo assess biosimilarity between a single dose from the test product versus the reference product in healthy participants\n\nSecondary objective:\n\nTo investigate the safety and tolerability of the formulations. This study is a randomized single-dose, two-way, two-period, two-sequence, crossover biosimilarity study with a washout period of one week after each dosing.A minimum of 21 healthy adult male and female participants from Egyptian population will be enrolled in this study, along with 5 additional participants to account for potential dropouts or withdrawal. 26 Participants plus 1-4 alternates will be admitted to the study. An alternate participant will be dosed by the same sequence as the withdrawn participant only if any participant of the first 26 Participants withdraws before the first study drug administration. Withdrawals after study drug administration will not be replaced. All participants will be healthy adults aged (21-55) years, with a BMI within the accepted range of 18.5-30 kg\u002Fm², and will meet the study's selection criteria.",[28,185],"The Focus of the Study is to Determine the Comparative Pharmacodynamic of Enoxaparin Sodium With That of Clexane in Healthy Human Participants",[187,188,189,190,191,192],"Enoxaparin Sodium","Pharmacodynamics","Clexane","Randomized","Healthy participants","single dose","2026-04-01",{"date":195,"type":40},"2026-04-08",{"date":197,"type":22},"2026-04-30",{"date":199,"type":22},"2026-08",{"name":201,"class":47},"Egyptian International Pharmaceutical Industries Co",{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":16,"sex":56,"minAge":18,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":23,"phases":211,"briefSummary":213,"conditions":214,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":48},"100624226","positive-psychology---based-eml-for-enhancing-well-being-100624226","NCT07406880","Positive Psychology - Based EMl for Enhancing Well-Being","Positive Psychology-Based Ecological Momentary Intervention for Well-Being in College Students: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Participants in our study are healthy college students.\n* Have smartphone, and have access to the internet.\n\nExclusion Criteria:\n\n* Unable to use a smartphone.\n* Have significant cognitive impairment that prevents participation in the research",{"count":210,"type":22},354,[212],"NA","This study aims to evaluate the acceptability and effectiveness of a positive psychology-based ecological momentary intervention (EMI) for enhancing well-being in college students. A three-arm randomized controlled trial (RCT) will assess the impact of a dynamic EMI that delivers personalized exercises when participants' real-time affect or well-being scores fall below a predefined threshold, compared to control conditions. Primary outcomes include changes in well-being and mental health, evaluated through a mixed-methods approach combining quantitative measures and qualitative interviews.",[28],"2026-02-06",{"date":217,"type":40},"2026-02-12",{"date":219,"type":22},"2026-02-01",{"date":221,"type":22},"2026-12-30",{"name":223,"class":127},"The Hong Kong Polytechnic University",{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":16,"sex":56,"minAge":19,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":23,"phases":233,"briefSummary":234,"conditions":235,"keywords":237,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":4},"100599355","impact-of-digital-oral-health-educational-program-on-a-group-of-geriatrics-oral-health-and-quality-of-life-compared-to-standard-oral-health-educational-program-in-egypt-100599355","NCT07083414","Impact of Digital Oral Health Educational Program on a Group of Geriatrics Oral Health and Quality of Life Compared to Standard Oral Health Educational Program in Egypt","Impact of Digital Oral Health Educational Program on a Group of Geriatrics Oral Health and Quality of Life Compared to Standard Oral Health Educational Program in Egypt: a Cluster Randomized Control Trial","Inclusion Criteria:\n\n* Old age population above years old.\n* Participants who is willing to confirm consent for the educational program and assessment.\n* Participants without disability that interfere during communication.\n\nExclusion Criteria:\n\n* Individuals with palliative care and rehabilitation ward, presence of mental disorder, had dangerous communicable disease.\n* Participants who refused to participate.",{"count":232,"type":22},40,[212],"The aim of the study is to evaluate the impact of a digital oral health education program on the oral health status and quality of life for geriatric populations compared to standard oral health education in Egypt.",[236,28],"Oral Health Self-efficacy",[238,239,240],"Educational program","Oral health program","Quality of life","2025-07-23",{"date":243,"type":40},"2025-07-28",{"date":245,"type":22},"2025-12-01",{"date":247,"type":22},"2026-06-15",{"name":249,"class":127},"Cairo University",{"id":251,"slug":252,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":16,"sex":56,"minAge":4,"maxAge":4,"enrollmentInfo":257,"targetDuration":4,"studyType":23,"phases":258,"briefSummary":259,"conditions":260,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":48},"100580906","act-based-emi-in-college-students-100580906","NCT06843395","ACT-based EMI in College Students","Assessing the Feasibility, Acceptability and Effectiveness of an Transdiagnostic Acceptance and Commitment Therapy-based Ecological Momentary Intervention in College Students: a Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n* Participants in our study are healthy college students\n* have smartphone, and have access to the internet\n\nExclusion Criteria:\n\n* currently participating in another research\n* have significant cognitive impairment that prevents participation in the research",{"count":136,"type":22},[212],"This study aims to evaluate the acceptability and effectiveness of a transdiagnostic, Acceptance and Commitment Therapy (ACT)-based ecological momentary intervention (EMI) among college students. A mixed-methods pilot randomized controlled trial (RCT) will be conducted to assess its impact on psychological flexibility, well-being and mental health outcomes.",[28],"2025-03-06",{"date":263,"type":40},"2025-03-11",{"date":265,"type":22},"2025-04-15",{"date":267,"type":22},"2025-12-31",{"name":223,"class":127}]